Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon p...
CSafe's custom thermal shipper for Krystal maintains -20°C throughout the product journey to help ensure that doses of Vyjuvek reach clinicians and pat...
The cell & gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver...
Published online May 16 in the journal Cell, the report describes the molecular mechanism behind a DNA repair pathway that counters the mistaken inclusion ...
Synthego Corp., a leading provider of genome engineering solutions, has announced a victory in its dispute with Agilent Technologies, Inc., regarding two o...
Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development...
"The biosafety level 2 lab space at the University of Guelph will expand CATTI's offering in central Canada and provide hands-on-learning in a one-of-a-kin...
SonoThera and Janssen Pharmaceuticals, Inc. have entered into a research collaboration agreement to develop a novel approach for deli...
GE HealthCare (Nasdaq: GEHC) is presenting three new global innovations – Intelligent Radiation Therapy (iRT), Auto Segmentation, and an updated Magn...
OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Kor...
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the ...
Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...
The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior ...
The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...
© 2024 Biopharma Boardroom. All Rights Reserved.
